The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
Phones:
+7 (495) 482-4118
+7 (495) 482-4329
  • Toll-free number for subscriptions:
    +8 800 250-18-12
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Spirin N.N.

Yaroslavl State Medical University

Vlasov Ya.V.

Samara State Medical University

Zakharova M.N.

Research Center of Neurology

Khachanova N.V.

Pirogov Russian National Research Medical University;
City Clinical Hospital No. 24

Popova E.V.

Tambov branch of S.N. Fyodorov National Medical Research Center «MNTK «Eye Microsurgery»

Khabirov F.A.

Kazan State Medical Academy

Totolian N.A.

Pavlov First St. Petersburg State Medical University

Sivertseva S.A.

Tyumen Regional Center for Multiple Sclerosis

Goncharova Z.A.

Rostov State Medical University

Korsunskaya L.L.

Simferopol City Clinical Hospital No. 7

Yakushina T.I.

Vladimirsky Moscow Regional Research Clinical Institute

Matveevskaya O.V.

Moscow Society of Multiple Sclerosis

Simaniv T.O.

Research Center of Neurology

Boyko A.N.

Pirogov National Research Medical University;
Federal Center for Brain Research and Neurotechnologies

New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»)

Authors:

Spirin N.N., Vlasov Ya.V., Zakharova M.N., Khachanova N.V., Popova E.V., Khabirov F.A., Totolian N.A., Sivertseva S.A., Goncharova Z.A., Korsunskaya L.L., Yakushina T.I., Matveevskaya O.V., Simaniv T.O., Boyko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7‑2): 84‑88

DOI: 10.17116/jnevro202212207284

Read: 3303 times

Contact the author
Table of contents

NEW OPPORTUNITIES IN THE TREATMENT OF PATIENTS WITH MULTIPLE SCLEROSIS (RESOLUTION OF THE COUNCIL OF EXPERTS ON APRIL 23, 2022, MOSCOW, JSC «BIOCAD»)
NEW OPPORTUNITIES IN THE TREATMENT OF PATIENTS WITH MULTIPLE SCLEROSIS (RESOLUTION OF THE COUNCIL OF EXPERTS ON APRIL 23, 2022, MOSCOW, JSC «BIOCAD»)

To cite this article:

Spirin NN, Vlasov YaV, Zakharova MN, et al. New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»). S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7‑2):84‑88. (In Russ.)
https://doi.org/10.17116/jnevro202212207284

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Esti­mation of pro-inflammatory cyto­kines and C-reactive protein levels in patients with acute demye­lination episode. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):118-121
Features of depressive diso­rders and suicidal beha­vior in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):7-13
Search for info­rmative predictors of the deve­lopment and progression of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):124-130
Modern methods of reha­bilitation of patients with different degrees of multiple scle­rosis. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(5):48-55
Factors and features of the deve­lopment of epilepsy in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):18-27
Comparison of methods for asse­ssing the seve­rity of multiple scle­rosis based on a sample of patients from the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):121-127
Clinical and demo­graphic features of multiple scle­rosis in the Krasnoyarsk Krai. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(1):120-125
Clinico-demographic characteristics and immu­nological cere­brospinal fluid markers in patients with headache and multiple scle­rosis. Russian Journal of Pain. 2026;(1):5-11
Vertebrogenic pain syndromes in patients with multiple scle­rosis. Russian Journal of Pain. 2026;(1):64-71
Age-related aspe­cts of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(4):62-68
Abstract:

One of the target areas for the development of the Russian pharmaceutical industry at present is the development of next-in-class drugs medicines. These are original, patent-protected drugs that act on known biological targets, improved or modified in structure and mechanism of action compared to existing, successfully proven medicine. The article presents the results of an expert council on the management of patients with multiple sclerosis and the place of new original medicines of the JSC BIOCAD company (SamPEG-IFN-β1a and divozilimab) in multiple sclerosis therapy algorithm.

Keywords:

multiple sclerosis
next-in-class medicine
SamPEG-IFN-β1a
divozilimab

Authors:

Spirin N.N.

Yaroslavl State Medical University

Vlasov Ya.V.

Samara State Medical University

Zakharova M.N.

Research Center of Neurology

Khachanova N.V.

Pirogov Russian National Research Medical University;
City Clinical Hospital No. 24

Popova E.V.

Tambov branch of S.N. Fyodorov National Medical Research Center «MNTK «Eye Microsurgery»

Khabirov F.A.

Kazan State Medical Academy

Totolian N.A.

Pavlov First St. Petersburg State Medical University

Sivertseva S.A.

Tyumen Regional Center for Multiple Sclerosis

Goncharova Z.A.

Rostov State Medical University

Korsunskaya L.L.

Simferopol City Clinical Hospital No. 7

Yakushina T.I.

Vladimirsky Moscow Regional Research Clinical Institute

Matveevskaya O.V.

Moscow Society of Multiple Sclerosis

Simaniv T.O.

Research Center of Neurology

Boyko A.N.

Pirogov National Research Medical University;
Federal Center for Brain Research and Neurotechnologies

Received:

07.06.2022

Accepted:

07.06.2022

Close metadata

References:

  1. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-286.  https://doi.org/10.1212/WNL.0000000000000560
  2. Boyko AN, Gusev EI. Modern algorithms for the diagnosis and treatment of multiple sclerosis based on an individual assessment of the patient’s condition. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2017;2(2):92-106. (In Russ.). https://doi.org/10.17116/jnevro20171172292-106
  3. Cutter G, Veneziano A, Grinspan A, et al. Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS. Mult Scler Relat Disord. 2019;33:13-21.  https://doi.org/10.1016/j.msard.2019.04.036
  4. Vostokova NV, Trakhtenberg YuA, Smolyarchuk EA, Svistunov AA. Possibilities of changing adaptive design in clinical trials. Biluten Nauchnogo Centrs dlyi Issltdovaniy Medicinckch Productov. 2016;(4):36-41. (In Russ.).
  5. Reuss R. PEGylated interferon beta-1a in the treatment of multiple sclerosis — an update. Biol: Targ Ther. 2013;7:131-138.  https://doi.org/10.2147/BTT.S29948
  6. Tolley K, Hutchinson M, You X, et al. A network meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated interferon beta-1a versus other injectable therapies for the treatment of relapsing-remitting multiple sclerosis. PLoS One. 2015;10(6):e0127960. https://doi.org/10.1371/journal.pone.0127960
  7. Melnikov MV, Kasatkin DS, Volkov AI, Boyko AN. Pegylated form of interferon beta in the therapy of multiple sclerosis. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2019;119(8):136-141. (In Russ.). https://doi.org/10.17116/jnevro2019119081136
  8. Boyko AN, Bakhtiyarova KZ, Dudin VA, et al. A new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2019;119(10, issue 2):100-109. (In Russ.). https://doi.org/10.17116/jnevro2019119102100
  9. Boyko AN, Boyko OV, Bakhtiyarova KZ, et al. Efficacy and safety of sampeginterferon β-1a for the treatment of remitting multiple sclerosis: results of a 52-week randomized double-blind clinical trial. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2022;122(1):62-71. (In Russ.). https://doi.org/10.17116/jnevro202212201162
  10. Newsome SD, Scott TF, Arnold DL, et al. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN. Ther Adv Neurol Disord. 2018;11:1756286418791143. https://doi.org/10.1177/1756286418791143
  11. Boyko OV, Boyko AN, Yakovlev PA, et al. Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety. Zh Nevrol Psikhiatr im. S.S. Korsakova. 2019;119(10. Vyp. 2):87-95. (In Russ.). https://doi.org/10.17116/jnevro201911910287
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.